DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious vascular diseases, particularly acute ischemic stroke (AIS) and preeclampsia (PE). Their lead product candidate, DM199 (rinvecalinase alfa), aims to restore normal levels of the naturally occurring protein KLK1, which is believed to play a crucial role in regulating blood flow and reducing inflammation. By increasing collateral circulation and improving blood flow to ischemic tissue, DM199 has the potential to improve patient outcomes in both AIS and PE, where current treatment options are limited.

DiaMedica has achieved several milestones in its development, including completing Phase 2 clinical trials for DM199 in AIS, demonstrating its safety and potential efficacy. The company is currently conducting a pivotal Phase 2/3 trial (ReMEDy2) in AIS patients who do not have access to other therapeutic options, aiming to prove the drug's efficacy and pave the way for potential regulatory approval. DiaMedica's commitment to research and development, along with its promising pipeline, positions it as a potential leader in the treatment of vascular diseases with significant unmet medical needs.

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of individuals battling serious vascular diseases by developing innovative therapies that reduce ischemia. Their primary focus is on developing DM199, a recombinant protein replacement therapy, to treat acute ischemic stroke (AIS) and preeclampsia (PE) by restoring normal levels of the KLK1 protein. This novel approach centers on improving blood flow to ischemic tissue (collateral circulation) to ultimately improve patient outcomes and redefine what's possible for individuals with these serious vascular diseases.

DiaMedica Therapeutics Inc. fosters a collaborative and high-energy work environment that values creativity and innovation. They seek passionate individuals who are committed to making a lasting impact in the field of biotechnology, particularly in the development of new treatments for acute ischemic stroke and preeclampsia. This dedication to advancing medical knowledge and improving patient care is central to their company culture, as evidenced by their emphasis on clinical research and their strong partnerships with physician investigators and trial participants.

DiaMedica Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace that values and respects the unique contributions of all employees. The company strives to create a culture where all individuals feel welcome, respected, and empowered to reach their full potential, regardless of their background, identity, or beliefs.